vs

Side-by-side financial comparison of MEDIFAST INC (MED) and McCormick & Company (MKC). Click either name above to swap in a different company.

McCormick & Company is the larger business by last-quarter revenue ($1.9B vs $75.1M, roughly 24.6× MEDIFAST INC). On growth, McCormick & Company posted the faster year-over-year revenue change (2.9% vs -36.9%). Over the past eight quarters, McCormick & Company's revenue compounded faster (7.5% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

McCormick & Company, Incorporated is an American food company that manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavoring products to retail outlets, food manufacturers, and food service businesses.

MED vs MKC — Head-to-Head

Bigger by revenue
MKC
MKC
24.6× larger
MKC
$1.9B
$75.1M
MED
Growing faster (revenue YoY)
MKC
MKC
+39.8% gap
MKC
2.9%
-36.9%
MED
Faster 2-yr revenue CAGR
MKC
MKC
Annualised
MKC
7.5%
-34.4%
MED

Income Statement — Q4 2025 vs Q4 2025

Metric
MED
MED
MKC
MKC
Revenue
$75.1M
$1.9B
Net Profit
$226.6M
Gross Margin
69.4%
38.9%
Operating Margin
-10.4%
16.8%
Net Margin
12.2%
Revenue YoY
-36.9%
2.9%
Net Profit YoY
5.3%
EPS (diluted)
$-1.64
$0.84

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
MKC
MKC
Q4 25
$75.1M
$1.9B
Q3 25
$89.4M
$1.7B
Q2 25
$105.6M
$1.7B
Q1 25
$115.7M
$1.6B
Q4 24
$119.0M
$1.8B
Q3 24
$140.2M
$1.7B
Q2 24
$168.6M
$1.6B
Q1 24
$174.7M
$1.6B
Net Profit
MED
MED
MKC
MKC
Q4 25
$226.6M
Q3 25
$-2.3M
$225.5M
Q2 25
$2.5M
$175.0M
Q1 25
$-772.0K
$162.3M
Q4 24
$215.2M
Q3 24
$1.1M
$223.1M
Q2 24
$-8.2M
$184.2M
Q1 24
$8.3M
$166.0M
Gross Margin
MED
MED
MKC
MKC
Q4 25
69.4%
38.9%
Q3 25
69.5%
37.4%
Q2 25
72.6%
37.5%
Q1 25
72.8%
37.6%
Q4 24
74.1%
40.2%
Q3 24
75.4%
38.7%
Q2 24
73.2%
37.7%
Q1 24
72.8%
37.4%
Operating Margin
MED
MED
MKC
MKC
Q4 25
-10.4%
16.8%
Q3 25
-4.6%
16.7%
Q2 25
-1.0%
14.8%
Q1 25
-1.1%
14.0%
Q4 24
0.6%
17.0%
Q3 24
1.5%
17.1%
Q2 24
-4.7%
14.2%
Q1 24
4.5%
14.6%
Net Margin
MED
MED
MKC
MKC
Q4 25
12.2%
Q3 25
-2.5%
13.1%
Q2 25
2.3%
10.5%
Q1 25
-0.7%
10.1%
Q4 24
12.0%
Q3 24
0.8%
13.3%
Q2 24
-4.8%
11.2%
Q1 24
4.8%
10.4%
EPS (diluted)
MED
MED
MKC
MKC
Q4 25
$-1.64
$0.84
Q3 25
$-0.21
$0.84
Q2 25
$0.22
$0.65
Q1 25
$-0.07
$0.60
Q4 24
$0.08
$0.79
Q3 24
$0.10
$0.83
Q2 24
$-0.75
$0.68
Q1 24
$0.76
$0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
MKC
MKC
Cash + ST InvestmentsLiquidity on hand
$167.3M
$95.9M
Total DebtLower is stronger
$3.6B
Stockholders' EquityBook value
$198.9M
$5.7B
Total Assets
$248.0M
$13.2B
Debt / EquityLower = less leverage
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
MKC
MKC
Q4 25
$167.3M
$95.9M
Q3 25
$173.5M
$94.9M
Q2 25
$162.7M
$124.1M
Q1 25
$164.6M
$102.8M
Q4 24
$162.3M
$186.1M
Q3 24
$170.0M
$200.8M
Q2 24
$163.5M
$166.3M
Q1 24
$156.4M
$178.0M
Total Debt
MED
MED
MKC
MKC
Q4 25
$3.6B
Q3 25
$3.9B
Q2 25
$3.9B
Q1 25
$3.9B
Q4 24
$3.9B
Q3 24
$3.4B
Q2 24
$4.1B
Q1 24
$4.1B
Stockholders' Equity
MED
MED
MKC
MKC
Q4 25
$198.9M
$5.7B
Q3 25
$214.7M
$5.8B
Q2 25
$216.0M
$5.6B
Q1 25
$211.0M
$5.4B
Q4 24
$210.1M
$5.3B
Q3 24
$207.3M
$5.4B
Q2 24
$205.3M
$5.3B
Q1 24
$211.0M
$5.2B
Total Assets
MED
MED
MKC
MKC
Q4 25
$248.0M
$13.2B
Q3 25
$268.2M
$13.2B
Q2 25
$269.3M
$13.2B
Q1 25
$280.0M
$12.9B
Q4 24
$284.2M
$13.1B
Q3 24
$291.2M
$13.2B
Q2 24
$293.5M
$13.0B
Q1 24
$302.8M
$12.9B
Debt / Equity
MED
MED
MKC
MKC
Q4 25
0.63×
Q3 25
0.67×
Q2 25
0.69×
Q1 25
0.71×
Q4 24
0.73×
Q3 24
0.63×
Q2 24
0.77×
Q1 24
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
MKC
MKC
Operating Cash FlowLast quarter
$-5.3M
$542.0M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
2.39×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
MKC
MKC
Q4 25
$-5.3M
$542.0M
Q3 25
$12.1M
$258.8M
Q2 25
$-3.4M
$45.9M
Q1 25
$3.4M
$115.5M
Q4 24
$-4.9M
$458.7M
Q3 24
$9.1M
$161.7M
Q2 24
$13.1M
$163.1M
Q1 24
$7.3M
$138.4M
Free Cash Flow
MED
MED
MKC
MKC
Q4 25
$-6.6M
Q3 25
$10.8M
$206.1M
Q2 25
$-4.8M
$-2.4M
Q1 25
$1.9M
$78.4M
Q4 24
$-7.2M
Q3 24
$7.7M
$102.7M
Q2 24
$11.1M
$94.8M
Q1 24
$5.4M
$76.4M
FCF Margin
MED
MED
MKC
MKC
Q4 25
-8.8%
Q3 25
12.0%
11.9%
Q2 25
-4.5%
-0.1%
Q1 25
1.6%
4.9%
Q4 24
-6.1%
Q3 24
5.5%
6.1%
Q2 24
6.6%
5.8%
Q1 24
3.1%
4.8%
Capex Intensity
MED
MED
MKC
MKC
Q4 25
1.8%
Q3 25
1.5%
3.1%
Q2 25
1.3%
2.9%
Q1 25
1.3%
2.3%
Q4 24
1.9%
Q3 24
1.0%
3.5%
Q2 24
1.1%
4.2%
Q1 24
1.1%
3.9%
Cash Conversion
MED
MED
MKC
MKC
Q4 25
2.39×
Q3 25
1.15×
Q2 25
-1.36×
0.26×
Q1 25
0.71×
Q4 24
2.13×
Q3 24
8.04×
0.72×
Q2 24
0.89×
Q1 24
0.88×
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

MKC
MKC

Consumer$1.1B61%
Flavor Solutions$723.1M39%

Related Comparisons